Hanson Jason David 4
4 · Valeant Pharmaceuticals International, Inc. · Filed Dec 13, 2012
Insider Transaction Report
Form 4
Hanson Jason David
EVP, Company Group Chairman
Transactions
- Award
Restricted Share Units
2012-12-11+36,300→ 36,300 totalExercise: $0.00→ Common Shares, no par value (36,300 underlying) - Award
Non-Qualified Stock (right to purchase)
2012-12-11+84,500→ 84,500 totalExercise: $58.16From: 2016-12-11Exp: 2022-12-11→ Common Shares, no par value (84,500 underlying)
Footnotes (3)
- [F1]The options vest 25% per year for 4 years starting from the date of grant with the first vest date falling on the first anniversary of the grant, the second vest date falling on the second anniversary of the grant, the third vest date falling on the third anniversary of the grant and the fourth vest date falling on the fourth anniversary of the grant.
- [F2]Each Restricted Share Unit ("RSUs") represents a contingent right to receive between zero and three common shares, no par value, of Valeant Pharmaceuticals International, Inc. ("Valeant"), subject to performance based vesting criteria. See note (3).
- [F3]The performance based RSUs are eligible to vest on the achievement of TSR targets ranging from 10% to 30% over a base price of $55.66 on each of three measurement dates: 25% would vest on September 11, 2015, 50% on December 11, 2015 and 25% on March 11, 2016, with early vesting possible at higher TSR levels.